GAC - The short answer is and will always be yes BP can afford apabetalone. As well as any cash they may have sitting around and credit available they have an almost endless currency called stock. There has been many deals over the years that have involved a combination of cash and shares of the acquiring company that could satisfy an agreed upon purchase price.

As for valuation, we will find that out the further we proceed in this trial. It could be very low or very high but likely nowhere close to where the share price currently is. One thing I have found with past investments is that once good news starts to flow, analyst after analyst begin to not only catch onto a story for fear of missing out on the next big thing but tend to update their analysis as more possibilities are factored into their models. 

The balance of this year is going to be quite interesting for the shareholders. 2019 could be even more interesting as, if the science is successful and if we have to wait for the full data set to close a deal it will be next year, IMO.

My model shows possibilities that would not be acceptable to put in print on this board so we will just have to see how this plays out. IMO if the science proves to do what the presentations suggest it could do, there is at least a chance apabetalone could set a new record for the highest sales of any drug in a one year period of any drug in the world. If we don't pass this trial it will be quite a challenge to look at the share price. If the science is proved I do not believe apabetalone will be a blockbuster, I believe it will be a mega-blockbuster.

Since I still hold my position you have a good idea of my thoughts.

All IMO, dyodd.

tada